“…In the context of immunotherapy, Marandino et al recently reported that [ 18 F]-FDG PET/CT would have prevented 7% of patients with non-enlarged lymph nodes (<8 mm) from inappropriately receiving neoadjuvant pembrolizumab. 11,12 Some results support the idea that interpretation criteria in [ 18 F]-FDG PET/CT should be adjusted according to the size of the nodes. 13 While a mild uptake can lead to classifying enlarged lymph nodes as cN+, strong uptake should be required for small ones to avoid false positives.…”